Miltefosine to Treat Cutaneous Leishmaniasis in Bolivia
Miltefosine to Treat Cutaneous Leishmaniasis in Bolivia
Cutaneous leishmaniasis is typically treated with the parenteral product pentavalent
 antimony. Miltefosine is an oral agent shown to be active for mucosal leishmaniasis due to L
 braziliensis in Bolivia and cutaneous leishmaniasis due to L panamensis in Colombia. This
 trial is intended to evaluate miltefosine for cutaneous leishmaniasis due to L braziliensis
 in Bolivia. Patients will be randomly assigned to miltefosine or pentavalent antimony.
 Standard dose regimens will be used for both drugs.
Presentation: At least 1 lesion must be ulcerative. Parasitology: Parasitological
 confirmation of 1 lesion will be made by visualization or culture of leishmania from the
 biopsy or aspirate of the lesion.

 Previous RX: No specific or putatively specific therapy for leishmaniasis (Sb, pentamidine,
 amphotericin B, imidazoles, allopurinol)

 Other diseases: No concomitant diseases by history and by approximately normal complete
 blood counts (white blood count, hemoglobin, platelet count), values of liver transaminases
 (SGOT) and kidney function tests (creatinine).